The epidemiology of end-stage renal disease in Iran in an international perspective

被引:60
作者
Haghighi, AN
Broumand, B
D'Amico, M
Locatelli, F
Ritz, E
机构
[1] Osped A Manzoni, Azienda Osped Lecco, Dept Nephrol & Dialysis, I-23900 Lecco, Italy
[2] Shahid Beheshti Univ Med Sci, Taleghani Univ Hosp, Tehran, Iran
[3] Univ Med Sci Iran, Rasoul Akram Univ Hosp, Tehran, Iran
[4] Univ Heidelberg, Dept Nephrol, Heidelberg, Germany
关键词
D O I
10.1093/ndt/17.1.28
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 [基础医学]; 1002 [临床医学]; 100602 [中西医结合临床];
摘要
Introduction. The epidemiology of end-stage renal disease (ESRD) and renal replacement therapy (RRT) is under continuous evolution all over the world. We report here the epidemiological analysis of ESRD and RRT in Iran and discuss it against the background of the international situation. Methods. This epidemiological report is based on data from centre questionnaires which were collected in Iran from 1997 onwards, with a response rate of 100%. Results. The prevalence/incidence of RRT patients were 238/49.9 p.m.p. in the year 2000. Haemodialysis and kidney transplantation were the most common RRT modalities, accounting for 53.7% and 45.5% of prevalent RRT patients, respectively. The proportion treated by peritoneal dialysis was very low (<1%). Home haemodialysis was not performed. The majority of haemodialysis centres used synthetic membranes (70%) and 100% of the sessions were performed using acetate as a buffer; 42.5% of haemodialysis patients were treated with a twice-weekly regimen, whilst 49.6% were on the standard thrice-weekly regimen. The majority of RRT patients in Iran were young to middle aged. The great majority of renal allografts came from living donors (mainly unrelated to recipients). The main renal diseases leading to ESRD were diabetes and hypertension. The third most common category was 'cause unknown. Conclusion. The epidemiology of RRT in Iran is characterized by: (i) young patient age (younger than the international average); (ii) high proportion of patients receiving renal allograft; (iii) use of living-unrelated donors as the major source of renal allografts.
引用
收藏
页码:28 / 32
页数:5
相关论文
共 19 条
[1]
FAZEL I, 1995, TRANSPLANT P, V27, P2586
[2]
5-YEAR SURVIVAL FOR END-STAGE RENAL-DISEASE PATIENTS IN THE UNITED-STATES, EUROPE, AND JAPAN, 1982 TO 1987 [J].
HELD, PJ ;
BRUNNER, F ;
ODAKA, M ;
GARCIA, JR ;
PORT, FK ;
GAYLIN, DS .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1990, 15 (05) :451-457
[3]
*IT REG DIAL TRANS, 1998, REP
[4]
A study of the quality of life and cost-utility of renal transplantation [J].
Laupacis, A ;
Keown, P ;
Pus, N ;
Krueger, H ;
Ferguson, B ;
Wong, C ;
Muirhead, N .
KIDNEY INTERNATIONAL, 1996, 50 (01) :235-242
[5]
Duration of dialysis sessions - was Hegel right? [J].
Locatelli, F ;
Manzoni, C .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (03) :560-563
[6]
1983 TO 1992 - REPORT ON REGULAR DIALYSIS AND TRANSPLANTATION IN LOMBARDY [J].
LOCATELLI, F ;
MARCELLI, D ;
CONTE, F ;
LIMIDO, A ;
LONATI, F ;
MALBERTI, F ;
SPOTTI, D .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 25 (01) :196-205
[7]
The epidemiology of end-stage renal disease in the Baltic countries: an evolving picture [J].
Locatelli, F ;
D'Amico, M ;
Cernevskis, H ;
Dainys, B ;
Miglinas, M ;
Luman, M ;
Ots, M ;
Ritz, E .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (07) :1338-1342
[8]
Locatelli F, 2000, J NEPHROL, V13, pS20
[9]
Progress in dialysis technology:: membrane selection and patient outcome [J].
Locatelli, F ;
Valderrábano, F ;
Hoenich, N ;
Bommer, J ;
Leunissen, K ;
Cambi, V .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (08) :1133-1139
[10]
Locatelli F, 1999, J NEPHROL, V12, pS82